



# Jalosome – Pain reducing and anti-inflammatory gel for dermatitis in radio- and chemotherapy

### Specially developed

Jalosome<sup>®</sup> is the first and only product specially developed against dermatitis related to radio- and chemotherapy. Its local anti-inflammatory and pain reducing properties have also been studied in other skin inflammations such as GvHD.

### Patented mode of action

Jalosome<sup>®</sup> is a water-based gel with liposomes, a vesicular microstructure that transports the active ingredients through stratum corneum. In the deeper layers of the skin the microstructures are dissolved, enabling the active ingredients to have its pain reducing and anti-inflammatory action. The treatment and the effect occur from the deep layers towards the surface of the skin.

### Pain reducing, clinically documented

Jalosome<sup>®</sup> have clinically documented effect by significantly reducing pain as well as duration and intensity of inflammation [1].

#### Oil and fat free, can be used during therapy

The choice of the 7 ingredients in Jalosome<sup>®</sup> has had its basis in the scientifically supported theory of hydrophilic formulations and its advantage in radiotherapy related skincare [2].



The unique composition of Jalosome<sup>®</sup> is totally free from oils and fat, which make it suitable during radiotherapy. It can also be used in all stages of radiodermatitis, and independently of other topical treatments.

## Please contact us for samples and more information about Jalosome®

GHN Pharma Nordic AB

Martin Svahn Product Manager, Pharmacist <u>infonordic@ghnpharma.com</u> Office +46 31 303 33 99 Mobile +46 7093 50368

[2]. Gollins S, Gaffney C, Slada S, Swindell R. RCT on gentian violet versus hydrogel dressing for radiotherapy induced moist skin desquamation. J wound Care. 2008 Jun;17(6):268-270, 272, 274-5.

<sup>[1].</sup> Giovanni Presta, Andrea Puliatti, Loris Bonetti, Angela Tolotti, Davide Sari and Dario Valcarenghi. Effectivenesss of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in patient receivng head and neck radiotherapy associated with cetuximab: A case report and review. Int Wound J. 2019 Dec; 16(6): 1433-1439.